Skip to main content
. 2017 Jul 26;8(47):81936–81941. doi: 10.18632/oncotarget.19567

Figure 2. AF4-MLL is not sufficient to initiate leukemia in CB-CD34+ HSPCs.

Figure 2

A. Representative flow cytometry analysis of chimeric mice. Human engraftment (black) is identified as HLA.ABC+ CD45+ and includes lymphoid CD19+ cells (blue), comprising pre-B (CD10+) and pro-B (CD10-) fractions, myeloid CD33+/CD15- or CD33+/CD15+ cells (green) and CD34+ immature cells (either lymphoid- (CD19+) or myeloid-committed (CD33+)). B. Graft composition confirming normal multilineage engraftment in primografts. C. CD19+ graft analysis demonstrating normal, non-leukemic pro-B (CD10-) to pre-B (CD10+) B cell differentiation. D. Normal engraftment composition of the immature CD34+ fraction including B cell progenitors (CD34+CD19+; 55-80%) and myeloid progenitors (CD34+CD33+; 20-45%) (n = 42 mice). E. Left panel, percentage of primografts showing splenomegaly (spleen weight >0.1g) within the indicated genotypes (n = 56). Macroscopic images comparing normal vs enlarged spleens are shown. Middle-right panels, platelet, hemoglobin and WBC counts analyzed in the indicated primary and secondary recipients, revealing no sign of leukemia in reconstituted mice.